Crispr Therapeutics AG (1CG)
Market Closed
15 Jun, 20:00
€
45. 00
+1.44
+3.2939%
€
- Market Cap
- P/E Ratio
- Div Yield
24 Volume
-2.71 Eps
€ 43.56
Previous Close Want to track 1CG and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Crispr Therapeutics AG (1CG) Statistics
Valuation metrics
Market Cap -
Enterprise value -140.81M
Trailing P/E (ttm) -6.39
Forward P/E -
PEG ratio 0.34
Price/Sales (ttm) -
Price/Book (mrq) 2.19
Enterprise Value/Revenue -
Enterprise Value/EBITDA 0.22
Overview
Shares outstanding 96.39M
Float -
Shares short -
% Held by insiders -
% Held by institutions -
Average volume (10 days) 1
Average volume (90 days) 3
Price summary
52-Week low 35
52-Week high 68.5
Beta -
50-Day moving average 43.71
200-Day moving average 47.16
Dividends and splits
Forward annual dividend rate -
Forward annual dividend yield -
Trailing annual dividend rate -
Trailing annual dividend yield -
5-Year annual dividend yield -
Payout ratio -
Dividend Date -
Ex-Dividend Date -
Last split factor 333,333:100,000
Last split Date 19 Jul 2016
Financials
Fiscal year
Fiscal year ends 31 Dec 2025
Most recent quarter (mrq) 31 Mar 2026
Profitability
Profit margin -
Operating margin -
Operational effectiveness
Return on assets -0.26%
Return on equity -0.3%
Income Statement
Revenue (ttm) -
Revenue per share (ttm) -
Quarterly revenue growth (yoy) -
Gross profit (ttm) -213.48M
EBITDA -
Net income to common (ttm) -581.6M
Diluted EPS (ttm) -6.47
Quarterly earnings growth (yoy) -
Balance Sheet
Total cash (mrq) -
Total cash per share (mrq) -
Total debt (mrq) 787.64M
Total Debt/Equity (mrq) 0.43
Current ratio (mrq) 17.96%
Book value per share (mrq) 18.89
Cash Flow
Cash flow statement -393.25M
Levered free cash flow (LFCF) -581.6M
